Alnylam Pharmaceuticals, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Yvonne L. Greenstreet
- Full Time Employees
- 2,500
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 675 West Kendall Street Cambridge MA United States 02142
- IPO Date
- May 28, 2004
- CIK
- 0001178670
- Website
- alnylam.com
- Similar Companies
- Business
- Alnylam Pharmaceuticals, Inc. (ALNY) develops and commercializes RNA interference (RNAi) therapeutics targeting genetically defined diseases; core products include ONPATTRO (patisiran) for hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, AMVUTTRA (vutrisiran) for ATTR amyloidosis with polyneuropathy or cardiomyopathy, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1; the company also advances partnered programs such as Leqvio (inclisiran) for hypercholesterolemia marketed by Novartis. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam operates globally with key facilities in the US, Europe (including France, Italy, Netherlands, Sweden, Switzerland, and the UK), and Japan. The company maintains strategic collaborations with Roche on zilebesiran for hypertension, Regeneron for CNS diseases, Sanofi on fitusiran for hemophilia, and others including Novartis and Agios Pharmaceuticals. Recent developments encompass expansion of AMVUTTRA into ATTR cardiomyopathy with strong launch uptake and upgraded 2025 revenue guidance, initiation of a Phase 1 trial for ALN-4324 targeting GRB14 for type 2 diabetes, and Agios' IND clearance for AG-236 (ALN-TMP) in polycythemia vera; Alnylam joined the Alliance for Genomic Discovery in 2025 to leverage datasets for gene-silencing medicines and extended its partnership with Medison Pharma into LATAM and APAC markets. Pipeline advancements feature nucresiran for ATTR amyloidosis, mivelsiran for Alzheimer's disease and cerebral amyloid angiopathy, and positive Phase 3 data for zilebesiran. These efforts support Alnylam's transition to profitability with 2024 net product revenues exceeding $1.3 billion across rare and cardiometabolic indications.
Company News
Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership
Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026
Buy, Sell, or Hold? Today’s Top Upgrades and Downgrades: Amazon.com, Coinbase Global, CrowdStrike, FormFactor, GameStop, L3Harris Technologies, Oracle, Reddit, Rivian Automotive, and More
ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns
Lost Money on Alnylam Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Continues Investigating Possible Securities Fraud After 28.31% Share Price Drop
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call Transcript
Alnylam Pharmaceuticals Q3 Earnings Call Highlights
Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics
Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress
Alnylam (ALNY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease Transcript
Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial
Alnylam: Amvuttra Growth And Brezosiran Strengthen The Bull Case
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
34,533 Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Curated Wealth Partners LLC
Alnylam Pharmaceuticals, Inc. $ALNY Shares Newly Acquired by First Citizens Bank & Trust Co.